Last updated: August 1, 2026
Flunisolide is a mature, low-cost corticosteroid used mainly for allergic rhinitis and, historically, maintenance treatment of asthma. Its clinical development program is effectively complete. No active late-stage trial program, novel formulation pipeline, meaningful biologic competition, or material branded revenue base is publicly evident. Commercial demand is concentrated in generic nasal products, while inhaled flunisolide has largely exited routine U.S. use.
The market outlook is stable to declining in value. Volume may persist in price-sensitive markets, but flunisolide is structurally disadvantaged against newer intranasal corticosteroids such as fluticasone, mometasone and budesonide.
What is flunisolide and what products contain it?
Flunisolide is a synthetic glucocorticoid with anti-inflammatory activity. It binds intracellular glucocorticoid receptors and suppresses inflammatory mediator release, making it suitable for local treatment of nasal mucosal inflammation.
| Attribute |
Flunisolide |
| Drug class |
Intranasal and inhaled corticosteroid |
| Primary current use |
Allergic rhinitis |
| Historical respiratory use |
Maintenance treatment of asthma |
| Common nasal concentration |
0.025% |
| Common nasal dosage form |
Metered-dose nasal spray or solution |
| U.S. brand history |
Nasalide |
| Historical inhaled brand |
Aerobid |
| Prescription status |
Prescription product in the U.S. |
| Generic status |
Generic |
| FDA pathway |
Original NDA approvals followed by generic ANDA products |
| Biosimilar relevance |
None |
Flunisolide nasal products are administered locally and generally have lower systemic exposure than oral corticosteroids. The FDA labeling emphasizes regular use rather than immediate relief of acute nasal symptoms. Intranasal corticosteroids remain a standard class for allergic rhinitis, but flunisolide has lost share to products with stronger brand recognition, longer dosing intervals or broader over-the-counter availability.
What is the current clinical-trial status of flunisolide?
Flunisolide has no evident active pivotal development program. Its clinical evidence base consists primarily of older randomized studies evaluating nasal symptoms, asthma control, dose response, safety and comparisons with other corticosteroids.
ClinicalTrials.gov has historically included studies involving flunisolide or flunisolide-containing treatment arms, but the compound does not have a visible late-stage program comparable to newer anti-inflammatory or biologic therapies. Current clinical activity is limited by the drug's generic status, established mechanism and low commercial return on new trials.
Historical clinical evidence
Studies of intranasal flunisolide evaluated:
- Nasal congestion, rhinorrhea, sneezing and itching.
- Seasonal and perennial allergic rhinitis.
- Nasal corticosteroid dose response.
- Comparisons with beclomethasone, budesonide, fluticasone and related agents.
- Local adverse events, including epistaxis and nasal irritation.
- Systemic corticosteroid effects at standard doses.
Historical inhaled flunisolide studies evaluated maintenance treatment for asthma. The inhaled product has been commercially displaced by inhaled corticosteroids and combination inhalers with more established market access and prescribing support.
Clinical-trial outlook
A new flunisolide trial would need a differentiated objective, such as:
- A reformulated delivery system.
- A low-cost combination product.
- A pediatric or regional indication.
- A device with improved deposition or adherence.
- A fixed-dose combination with an antihistamine.
Without formulation or device differentiation, new trials would have limited commercial justification. The active pharmaceutical ingredient is old, inexpensive and clinically replaceable.
What is the FDA regulatory status of flunisolide?
FDA-regulated flunisolide nasal products have an established regulatory history. The original branded product, Nasalide, was approved for the treatment of seasonal and perennial allergic rhinitis. Generic versions entered through abbreviated new drug applications, allowing applicants to rely on the reference product's safety and efficacy findings while demonstrating pharmaceutical equivalence and bioequivalence or other applicable equivalence requirements.
Aerobid, the historical inhaled flunisolide product for asthma, is no longer a meaningful growth product in the U.S. market. Its commercial withdrawal does not imply that the active ingredient lacks pharmacologic activity; it reflects competitive displacement and market economics.
FDA product status
| Product category |
Current commercial position |
| Flunisolide nasal spray |
Generic, low-growth market |
| Nasalide brand |
Historical brand; limited or absent current commercial relevance |
| Aerobid inhaler |
Historical product; no material current U.S. growth platform |
| New molecular entity development |
None evident |
| New U.S. indication program |
None evident |
| Pediatric expansion program |
No material public program identified |
FDA labeling for generic flunisolide nasal spray identifies allergic rhinitis as the principal use. Product availability can vary by manufacturer, pharmacy channel and national market.
What patents protect flunisolide?
Flunisolide itself is an old small molecule and is not protected by a live composition-of-matter patent in the United States. Any original compound, formulation or early-use patents have expired or lost practical commercial significance.
The commercial patent position is therefore materially weaker than that of newer inhaled corticosteroids, combination inhalers or biologic therapies.
Patent estate assessment
| Patent category |
Current relevance |
| Composition-of-matter patent |
Expired |
| Original nasal formulation patents |
Expired or commercially inactive |
| Historical inhaler patents |
Expired or no longer commercially significant |
| Generic product patents |
No material blocking estate identified |
| Device patents |
Potentially relevant only to a differentiated product |
| Method-of-use patents |
Limited practical exclusivity |
| Orphan-drug exclusivity |
None |
| Biosimilar exclusivity |
Not applicable |
Generic flunisolide is not generally viewed as a product with meaningful remaining U.S. patent barriers. Any current patent risk would more likely arise from a newly developed device, formulation, combination or manufacturing process rather than from the active ingredient.
What is the Orange Book status of flunisolide?
The Orange Book historically listed approved flunisolide reference products and associated generic equivalents. The commercial significance of any listing depends on whether the reference product remains marketed and whether active patents or exclusivity periods remain.
For a mature generic nasal corticosteroid, Orange Book analysis should distinguish among:
- The original reference product.
- Approved generic ANDA products.
- Any listed patents, if present.
- Whether the reference product remains commercially available.
- Whether the listed product has current therapeutic substitution relevance.
No meaningful remaining New Drug Application exclusivity is expected for the legacy flunisolide products. A Paragraph IV challenge is therefore unlikely to create the same litigation exposure seen with newer products carrying active formulation or device patents.
When does flunisolide lose exclusivity?
Flunisolide lost core U.S. market exclusivity decades ago. Its composition, original clinical-use and legacy formulation protection no longer provides a commercial barrier to generic entry.
| Exclusivity type |
Status |
| New chemical entity exclusivity |
Expired |
| Composition patent |
Expired |
| Original product exclusivity |
Expired |
| Pediatric exclusivity |
No current material relevance |
| Orphan exclusivity |
Not applicable |
| Current market protection |
None of material commercial significance |
Because the product is generic, market entry depends on FDA approval, manufacturing economics, supply reliability and pharmacy contracting rather than patent clearance.
Which companies are challenging flunisolide, and what is the litigation status?
No material current patent litigation involving flunisolide is evident in the public drug-development landscape. The compound has been generic for many years, and its low unit price provides little incentive for branded patent litigation.
Potential entrants would normally file ANDAs rather than pursue a high-risk Paragraph IV strategy. For a legacy product with no commercially meaningful patent estate, applicants can generally enter through ordinary generic approval pathways, subject to FDA requirements and manufacturing capacity.
Litigation and settlement assessment
| Issue |
Current assessment |
| Active branded patent litigation |
No material public activity identified |
| Paragraph IV risk |
Low |
| Patent settlement agreements |
No commercially significant current settlement identified |
| ANDA competition |
Possible, subject to product availability |
| Antitrust exposure |
Low relative to protected branded products |
| Litigation-driven launch delay |
Unlikely |
What formulations are protected by flunisolide patents?
No legacy flunisolide formulation is known to retain a commercially meaningful patent barrier in the United States. A new formulation could create protectable intellectual property if it materially improves:
- Nasal deposition.
- Dose uniformity.
- Preservative tolerability.
- Pump performance.
- Pediatric administration.
- Once-daily adherence.
- Combination delivery with an antihistamine.
- Stability in high-temperature or high-humidity markets.
Such protection would attach to the new formulation, device or method, not to flunisolide as an active ingredient.
A commercial relaunch would require a differentiated product and a regulatory strategy that supports the claimed advantage. A simple reformulation with no clinically relevant benefit would face substitution by established generic products.
How strong is the flunisolide patent estate?
The legacy patent estate is weak. Its principal advantages are low development risk and a well-established safety record, not exclusivity.
| Patent-strength factor |
Assessment |
| Active ingredient protection |
Very weak |
| Formulation protection |
Weak for legacy products |
| Device protection |
Available only for new designs |
| Method-of-use protection |
Limited |
| Manufacturing know-how |
Potentially relevant but difficult to monetize |
| Freedom-to-operate risk |
Low for standard generic products |
| Litigation leverage |
Low |
| Licensing value |
Low unless tied to a new delivery technology |
Manufacturing know-how can still affect supply quality, particle size, suspension behavior, metering performance and regulatory compliance. Those factors may create operational barriers, but they are not equivalent to patent exclusivity.
What is the flunisolide market size and revenue outlook?
Public financial reporting generally does not separate flunisolide sales from broader generic respiratory portfolios. No reliable global consensus forecast for flunisolide revenue is widely reported by major pharmaceutical companies because the product is fragmented across manufacturers and sold at low prices.
The market is best assessed through a bottom-up framework:
- Prescription and institutional volume.
- Country-level generic availability.
- Average selling price.
- Nasal corticosteroid substitution.
- Manufacturer participation.
- Supply interruptions.
- Retail versus hospital demand.
2024-2030 market projection
The following projection is an analyst scenario rather than reported company guidance.
| Scenario |
Volume trend, 2024-2030 |
Net-price trend |
Revenue outlook |
| Base case |
-2% to -4% annually |
-1% to -3% annually |
Decline of roughly 20% to 35% |
| Downside case |
-5% to -8% annually |
-2% to -4% annually |
Decline of roughly 35% to 55% |
| Stabilization case |
Flat to +1% annually |
-1% to -2% annually |
Flat to decline of roughly 5% to 15% |
The base case assumes continued generic availability, gradual substitution by fluticasone and other intranasal corticosteroids, and no major product relaunch. The stabilization case requires stronger demand in emerging markets or a manufacturer to secure a durable institutional or regional supply position.
Revenue exposure
Flunisolide is unlikely to represent material revenue exposure for large multinational pharmaceutical companies. It may be strategically relevant to smaller generic manufacturers with concentrated respiratory portfolios, particularly where:
- The product has limited local competition.
- Procurement contracts reward low-cost supply.
- Alternative corticosteroids are unavailable or more expensive.
- Regulatory approval creates a local manufacturing advantage.
How does flunisolide compare with competing nasal corticosteroids?
| Product |
Commercial position |
Key competitive advantage |
| Flunisolide |
Mature generic |
Low cost and established history |
| Fluticasone propionate |
Strong generic and OTC presence |
Brand recognition, broad availability |
| Fluticasone furoate |
Branded and generic competition |
Once-daily positioning |
| Mometasone |
Strong generic and OTC presence |
Low systemic exposure and broad adoption |
| Budesonide |
Strong generic and OTC presence |
Broad market access and physician familiarity |
| Beclomethasone |
Generic and OTC presence in some markets |
Established nasal corticosteroid class position |
Flunisolide competes primarily on price. It lacks a clear dosing, device, efficacy or access advantage over the most widely used alternatives.
What generic entry risks exist for flunisolide?
Generic entry risk is already realized rather than prospective. The relevant commercial risks are further price erosion, product discontinuation and supply consolidation.
Key risks
- Additional low-cost generic entrants.
- Contract losses in retail or institutional channels.
- Substitution by OTC intranasal corticosteroids.
- Manufacturer withdrawal caused by low margins.
- API supply disruption.
- Reduced physician familiarity.
- Preference for once-daily products.
- Competition from antihistamine-steroid combination sprays.
The main barrier to entry is economic, not legal. A manufacturer must achieve sufficient scale to support FDA compliance, pharmacovigilance, packaging and distribution at a low selling price.
What licensing deals involve flunisolide?
Flunisolide has limited standalone licensing value. The molecule is generic and lacks an active exclusivity platform. Any commercially meaningful licensing opportunity would likely involve:
- A novel nasal delivery device.
- A combination product.
- A regional commercialization agreement.
- A manufacturing or supply contract.
- A repurposing program supported by new clinical data.
No major recent global licensing transaction centered on legacy flunisolide is publicly prominent. Licensing interest is more likely to arise at the product-platform level than at the active-ingredient level.
Key Takeaways
- Flunisolide is a mature generic corticosteroid with no meaningful remaining composition-of-matter exclusivity.
- Current clinical development is limited; no active late-stage innovation program is evident.
- U.S. commercial use is concentrated in generic intranasal products.
- Historical inhaled flunisolide products have been commercially displaced.
- Orange Book and Paragraph IV risks are low compared with newer respiratory products.
- The legacy patent estate is weak; new value would require a protected device, formulation or combination.
- The 2024-2030 base-case revenue outlook is a decline of approximately 20% to 35%.
- Competitive pressure from fluticasone, mometasone and budesonide is likely to continue.
- Manufacturing reliability and low-cost supply are more important than patent strategy.
- Flunisolide has limited standalone licensing or acquisition value unless paired with differentiated delivery technology.
FAQs
Is flunisolide still FDA approved?
FDA-approved flunisolide nasal products have an established regulatory history, and generic products may remain available depending on manufacturer and market status. Product-level availability should be checked against current FDA databases and labeling.
Is flunisolide stronger than fluticasone?
Flunisolide and fluticasone are both intranasal corticosteroids, but fluticasone has stronger commercial adoption and broader availability. Comparative clinical performance depends on dose, formulation, adherence and patient response.
Can a company still patent a flunisolide product?
A company cannot obtain a new composition-of-matter patent on the old molecule itself. It may seek patents on a novel formulation, device, combination, manufacturing process or specific method of use if statutory requirements are met.
Does flunisolide have biosimilar competition?
No. Biosimilar regulation applies to biological products. Flunisolide is a chemically synthesized small molecule and competes through generic drug pathways.
Is flunisolide a good licensing or investment target?
Standalone flunisolide has limited licensing value because it is generic and commercially mature. The investment case would depend on a differentiated delivery system, protected combination product, regional supply advantage or unusually strong institutional demand.
References
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.). Flunisolide nasal spray prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Library of Medicine. (n.d.). Flunisolide. DrugBank and PubChem records. https://pubchem.ncbi.nlm.nih.gov/
-
National Library of Medicine. (2024). ClinicalTrials.gov. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (2024). Generic drugs: Questions and answers. https://www.fda.gov/drugs/questions-answers-generic-drugs
